L-carnitine administration in coronary artery disease and cardiomyopathy.
Myocardial ischaemia may be defined as a deficiency in cardiac energy supply relative to energy demand. In coronary artery disease (CAD), oxygen supply is limited due to coronary obstruction so energy production is not enough to meet the energy demands for work. Several reports involving about 2500 patients of CAD where carnitine was administered for upto 1 year indicate some beneficial effects. There is reduction in ischaemia showing reduced ST-segment depression and angina, greater effort tolerance and decreased need of cardiac drugs. Carnitine can cause overall improvement in cardiac performance in patients with CAD as well as in cardiomyopathy. More studies are necessary to demonstrate where carnitine can scavenge free radicals apart from its beneficial effect on fatty acid metabolism. Side effects of carnitine are mild nausea and vomiting and dose upto 2 g/day in 3 divided doses may not have any side effects. Intravenous L-carnitine acts rapidly and has no side effects.
NKP Salve Institute of Medical Sciences, Nagpur.
R B
RB
Singh
M
M
Aslam
D002331:Carnitine / Q000172:deficiency / Q000494:pharmacology / Q000627:therapeutic use*; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy*; D019587:Dietary Supplements; D006321:Heart / Q000187:drug effects; D006801:Humans; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000628:therapy
D002331:Carnitine